Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Ovarian cancer, drawn from the whole corpus: 240 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No effective screening.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
PARP resistance via BRCA reversion.
Also on OnCo: Resistance atlas · Lines of therapy.
Platinum-resistant disease is the hardest setting; three drugs with survival benefit arrived in 2023-26 and each adds months, so combining and sequencing them is the next step.
Also on OnCo: Resistance atlas · Lines of therapy.
Screening is unsolved: the UKCTOCS trial found no mortality reduction, so three-quarters of patients are still diagnosed at stage III-IV; opportunistic salpingectomy and multi-cancer blood tests are the live routes.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Platinum resistance is eventually near-universal in high-grade serous disease, and each new drug adds months, not years.
Also on OnCo: Resistance atlas · Lines of therapy.
PARP inhibitor resistance (BRCA reversion, restored fork protection) has no approved counter; later-line PARP use has been curtailed by OS signals.
Also on OnCo: Resistance atlas · Lines of therapy.
Immunotherapy fails in first-line disease; benefit is confined to PD-L1-positive platinum-resistant tumours.
Also on OnCo: Resistance atlas · Lines of therapy.
Clear-cell, mucinous, and carcinosarcoma have no subtype-specific approved therapy.
FRα-low patients are excluded from mirvetuximab; next-generation ADCs are not yet approved.
Access to HRD testing, PARP inhibitors, and ADCs is limited outside high-income countries.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Optimal duration of maintenance and ctDNA-guided de-escalation are untested.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 76 changes by month →When this page itself was last checked or edited.
Platinum-resistant PD-L1+ ovarian cancer
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
A milestone in how this cancer is treated.